ALLMedicine™ Dry Skin Center

Nov 16th, 2021 - Hand eczema is a common inflammatory skin disorder in both adolescence and adulthood. We sought to assess the lifetime prevalence of hand eczema and associated exogenous and endogenous risk factors among adolescents in Germany. This was a cross-se...

Nov 16th, 2021 - The SINATRA study is pilot study with a primary aim to explore the feasibility of the trial methodology. In addition, secondary objectives of the study will investigate if THz light is able to detect subtle differences in skin hydration and their ...

Nov 8th, 2021 - Filaggrin-derived natural moisturizing factors (NMF) play an important role in skin barrier function and in atopic dermatitis (AD). Its deficiency is associated with dry skin and increased surface pH. Studies on childhood environmental exposures a...

Nov 8th, 2021 - Clinical studies have clarified the usefulness of moisturizers for dry skin diseases. However, few reports exist on the appropriate application of moisturizers with respect to the skin physiological functions. To clarify the optimal moisturizer ap...

Nov 6th, 2021 - Factors predicting allergic sensitization in the first 6 months of life are poorly understood. We aimed to determine whether eczema, dry skin, and high transepidermal water loss (TEWL) at 3 months were associated with allergic sensitization at 6 m...

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

Nov 16th, 2021 - The SINATRA study is pilot study with a primary aim to explore the feasibility of the trial methodology. In addition, secondary objectives of the study will investigate if THz light is able to detect subtle differences in skin hydration and their ...

Oct 6th, 2021 - There are a total of 3 study visits, (some visits may be broken into separate visits per preference of subject), including socket fitting visits (which could be 2 separate visits), a baseline visit, and a final visit. During the socket visit, whic...

Aug 19th, 2021 - Double-blind placebo-controlled clinical trial to evaluate the effectiveness of a sterilized probiotic on skin health and hydration in adults with dry skin. The goal of the study is to determine if the addition of a skin-conditioning probiotic to ...

Jun 25th, 2021 - Every day the cells of the outer layer of skin die off, shed, and regenerate. When young, skin cells turn over quickly, but that turnover rate begins to slow with age, beginning as early as twenties. As a result, skin loses its luster and begins t...

May 21st, 2021 - Carpal tunnel syndrome is a clinical picture that occurs with a group of symptoms and signs as a result of compression and compression in the carpal tunnel where the median nerve passes to the wrist. Another name is hand-wrist canal disease, the m...

Nov 19th, 2021 - The FDA granted accelerated approval to the first drug to spur growth in kids with the most common form of dwarfism, the agency announced on Friday. Vosoritide (Voxzogo), a once-daily injectable treatment, is indicated for children 5 years and old...

Oct 6th, 2021 - Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies. BRAF and MEK inhibitors have numerous common side effects that can some...

Oct 6th, 2021 - Biliary tract cancers are an aggressive group of malignancies that historically have been very challenging to treat because of their anatomical location and limited responsiveness to systemic therapy.1-3 Biliary cancers arise from the epithelial l...

Sep 16th, 2021 - The FDA has granted premarket approval to the Oncomine Dx Target Test for use as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations who may be eligible to receiv...

Sep 16th, 2021 - The FDA granted accelerated approval to mobocertinib (Exkivity) as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, Takeda announced on Wednesday. Approval of...